5502 related articles for article (PubMed ID: 3089993)
1. Human IgM monoclonal anti-GD2 antibody: reactivity to a human melanoma xenograft.
Katano M; Saxton RE; Tsuchida T; Irie RF
Jpn J Cancer Res; 1986 Jun; 77(6):584-94. PubMed ID: 3089993
[TBL] [Abstract][Full Text] [Related]
2. Human monoclonal antibody to tumor-associated ganglioside GD2.
Katano M; Saxton RE; Irie RF
J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
[TBL] [Abstract][Full Text] [Related]
3. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
4. Human monoclonal antibody to ganglioside GD2-inhibited human melanoma xenograft.
Katano M; Jien M; Irie RF
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1053-9. PubMed ID: 6540688
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibody to tumor-associated ganglioside GD2: suppressed growth of human melanoma in nude mice.
Katano M; Irie RF
Immunol Lett; 1984; 8(4):169-74. PubMed ID: 6542067
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.
Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z
Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333
[TBL] [Abstract][Full Text] [Related]
8. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
[TBL] [Abstract][Full Text] [Related]
9. Human monoclonal antibody against ganglioside GD2: use in development of enzyme-linked immunosorbent assay for the monitoring of anti-GD2 in cancer patients.
Tai T; Cahan LD; Paulson JC; Saxton RE; Irie RF
J Natl Cancer Inst; 1984 Sep; 73(3):627-33. PubMed ID: 6206271
[TBL] [Abstract][Full Text] [Related]
10. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
11. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
12. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
13. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.
Saleh MN; Stapleton JD; Khazaeli MB; LoBuglio AF
J Immunol; 1993 Sep; 151(6):3390-8. PubMed ID: 8376782
[TBL] [Abstract][Full Text] [Related]
14. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
15. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside.
Basak S; Birebent B; Purev E; Somasundaram R; Maruyama H; Zaloudik J; Swoboda R; Strittmatter W; Li W; Luckenbach A; Song H; Li J; Sproesser K; Guerry D; Nair S; Furukawa K; Herlyn D
Cancer Immunol Immunother; 2003 Mar; 52(3):145-54. PubMed ID: 12649743
[TBL] [Abstract][Full Text] [Related]
16. Incorporation, remodeling and re-expression of exogenous gangliosides in human cancer cell lines in vitro and in vivo.
Nishio M; Furukawa K
Nagoya J Med Sci; 2004 May; 67(1-2):35-44. PubMed ID: 15279066
[TBL] [Abstract][Full Text] [Related]
17. Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 3.
Werkmeister JA; Triglia T; Mackay IR; Dowling JP; Varigos GA; Morstyn G; Burns GF
Cancer Res; 1987 Jan; 47(1):225-30. PubMed ID: 3791209
[TBL] [Abstract][Full Text] [Related]
18. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis.
Cheresh DA; Rosenberg J; Mujoo K; Hirschowitz L; Reisfeld RA
Cancer Res; 1986 Oct; 46(10):5112-8. PubMed ID: 3019521
[TBL] [Abstract][Full Text] [Related]
19. Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody.
Abdel-Wahab Z; Darrow T; Vervaert CE; Crowley NJ; Seigler HF
Mol Biother; 1991 Sep; 3(3):163-9. PubMed ID: 1768367
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]